Next Article in Journal
Anesthetic Efficacy of Dexmedetomidine versus Midazolam When Combined with Remifentanil for Percutaneous Transluminal Angioplasty in Patients with Peripheral Artery Disease
Previous Article in Journal
Effect of Pre-Hospital Intubation in Patients with Severe Traumatic Brain Injury on Outcome: A Prospective Cohort Study
Previous Article in Special Issue
Application of Diagnostic Interview for Internet Addiction (DIA) in Clinical Practice for Korean Adolescents
Article Menu
Issue 4 (April) cover image

Export Article

Open AccessArticle

The More You Take It, the Better It Works: Six-Month Results of a Nalmefene Phase-IV Trial

Addictive Behaviors Unit, Clinic Hospital, University of Barcelona, Barcelona 08036, Spain
Psychiatry Service, University of Salamanca Health Care Complex, Institute of Biomedicine, University of Salamanca, Salamanca 37007, Spain
Addictive Behavior Unit, Psychiatry Department, Hospital de la Santa Creu i Sant Pau Barcelona, Barcelona 08041, Spain
Addictive Behaviors Unit, Germanes Hospitalàries, Sant Boi, Barcelona 08830, Spain
Author to whom correspondence should be addressed.
J. Clin. Med. 2019, 8(4), 471;
Received: 19 February 2019 / Revised: 23 March 2019 / Accepted: 3 April 2019 / Published: 6 April 2019
(This article belongs to the Special Issue Assessment & Treatment of Addictions: New Tools for Old Problems)
PDF [568 KB, uploaded 23 April 2019]


Background: Alcohol use disorders remain a major health problem. Reduced drinking has been increasingly recognized as a valuable alternative to abstinence. Nalmefene has shown in previous, experimental studies to be a useful tool to aid reduced drinking. However, more data from routine practice settings are needed in order to obtain evidence with high external validity. The aim of this study was to conduct a single-arm phase-IV study with alcohol-dependent outpatients starting with nalmefene for the first time. Here, we present the main effectiveness analysis, scheduled at six months. Methods: This was an observational, multisite, single-arm, phase-IV study conducted among adult alcohol-dependent outpatients who received nalmefene for the first time. The study consisted of four visits: Baseline, 1 month, 6 months, and 12 months. At each visit, drinking variables were obtained from the time-line follow-back regarding the previous month. Satisfaction with medication was also assessed from both patients and professionals with the Medication Satisfaction Questionnaire. A repeated measures mixed model was performed for effective analysis regarding drinking outcomes (reduction in total alcohol consumption and the number of heavy drinking days). Regression analyses were performed in order to find predictors of responses to nalmefene. Results: From a total of 110 patients included, 63 reported data at the six-month visit. On average, patients took nalmefene 69% of days during the month previous to the 6-month assessment. Compared to the one month results, the number of heavy drinking days and total alcohol consumption increased. Still, they were significantly lower than baseline values (outcome evolution over time was from 13.5 to 6.8 to 9.4 days/month, and from 169 to 79 to 116 units/month). A total of 23 patients were considered medication responders. The number of days of taking nalmefene was significantly associated in the regression analysis. Satisfaction was globally high for both professionals and patients and, overall, nalmefene was well-tolerated with no serious adverse events reported. Conclusion: The data provided by this phase-IV study suggest that nalmefene is an effective, well-tolerated treatment for alcohol-dependence in real world, clinical settings. View Full-Text
Keywords: drinking reduction; nalmefene; phase-IV trial; 6 months; observational drinking reduction; nalmefene; phase-IV trial; 6 months; observational

Figure 1

This is an open access article distributed under the Creative Commons Attribution License which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited (CC BY 4.0).

Share & Cite This Article

MDPI and ACS Style

Barrio, P.; Roncero, C.; Ortega, L.; Guardia, J.; Yuguero, L.; Gual, A. The More You Take It, the Better It Works: Six-Month Results of a Nalmefene Phase-IV Trial. J. Clin. Med. 2019, 8, 471.

Show more citation formats Show less citations formats

Note that from the first issue of 2016, MDPI journals use article numbers instead of page numbers. See further details here.

Related Articles

Article Metrics

Article Access Statistics



[Return to top]
J. Clin. Med. EISSN 2077-0383 Published by MDPI AG, Basel, Switzerland RSS E-Mail Table of Contents Alert
Back to Top